亚洲 · 股市与财经 · Business Standard
Expanding innovative portfolio may drive gains for Sun Pharma stock
Lerodalcibep licensing deal, growth in the US portfolio and tariff relief offer triggers, while the proposed Organon acquisition could broaden its global reach
在 Business Standard 阅读全文 登录后可收藏MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.business-standard.com)
